• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)

    5/6/24 4:05:43 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIPO alert in real time by email
    SC 13D/A 1 g084225_13da.htm SC 13D/A

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D 

    Under the Securities Exchange Act of 1934 

    (Amendment No. 5)*

     

    LIPELLA PHARMACEUTICALS INC.
    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

    53630L100
    (CUSIP Number)

     

     David E. Danovitch, Esq.  

    Sullivan & Worcester LLP  

    1633 Broadway – 32nd Floor  

    New York, NY 10019  

    (212) 660-3000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
     
     May 2, 2024
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this Schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     

     

     

     

     CUSIP No. 53630L100 Amendment No. 5 to Schedule
    13D
     Page 2 of 5 Pages

     

     1 

    name of reporting persons 

     

    Jonathan H. Kaufman  

     
    2

    check the appropriate box if a member of a group*

     

    (a) ☐
    (b) ☐
    3

    sec use only

     

     
    4

    source of funds*

     

    PF, OO (1)  

     
    5

    check if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e)

     

    ☐
    6

    citizenship or place of organization

     

    United States  

     
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
      7

    sole voting power

     

    1,608,349 (2)   

     
    8

    shared voting power

     

    0 

     
    9

    sole dispositive power

     

    1,608,349 (2)   

     
    10

    shared dispositive power

     

    0  

     
    11

    aggregate amount beneficially owned by each reporting person

     

    1,608,349 (2) 

     
    12

    check box if the aggregate amount in row (11) excludes certain shares*

     

    ☐
    13

    percent of class represented by amount in row (11)

     

    19.3% (3) 

     
    14

    type of reporting person*

     

    IN  

     

    * SEE INSTRUCTIONS

     

    (1) Consists of (i) 888,849 shares of common stock, par value $0.0001 per share, of the issuer (“Common Stock”) purchased by Dr. Jonathan Kaufman (the “Reporting Person”) with personal funds, and (ii) 719,500 shares of Common Stock that may be issued upon exercise of stock options awarded by the issuer (“Issuer’) to the Reporting Person in his capacity as an officer and director of the Issuer, which are vested and exercisable within 60 days of the date of this Amendment No. 5 to Statement on Schedule 13D (this “Amendment No. 5”).

     

    (2) Consists of (i) 888,849 shares of Common Stock beneficially owned by the Reporting Person, (ii) fully vested options exercisable for 719,500 shares of Common Stock, and (iii) 26,666 unvested options which are exercisable within 60 days of the filing of this Amendment No. 5.

     

    (3) Calculated based on 7,605,636 shares of Common Stock outstanding as of the date of this Amendment No. 5, as verified with the Issuer. The 746,166 shares of Common Stock that the Reporting Person has the right to acquire within 60 days of the filing of this Amendment No. 5 are deemed to be outstanding for purposes of calculating the Reporting Person’s beneficial ownership percentage. 

     

     

     

     

     CUSIP No. 53630L100 Amendment No. 5 to Schedule
    13D
     Page 3 of 5 Pages

     

    This Amendment No. 5 amends and supplements the Statement on Schedule 13D, initially filed by the Reporting Person with the SEC on December 29, 2022, as amended by Amendment No. 1 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on June 21, 2023, as amended by Amendment No. 2 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on March 6, 2024, as amended by Amendment No. 3 to such Statement on Schedule 13D, filed by the Reporting Person with the SEC on March 15, 2024, and as further amended by Amendment No. 4 to such Statement on Schedule 13D (“Amendment No. 4”), filed by the Reporting Person with the SEC on March 19, 2024 (collectively, the “Schedule 13D”). Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D. Except as otherwise set forth herein, this Amendment No. 5 does not modify any of the information previously reported by the Reporting Person in the Schedule 13D.

     

    The purpose of this Amendment No. 5 is to update the Reporting Person’s beneficial ownership information in the Schedule 13D and to correct inadvertent administrative errors in Amendment No. 4 with respect to the number of stock options held by the Reporting Person that were exercisable within 60 days of the date of filing of Amendment No. 4, resulting in the reporting of higher voting power and beneficial ownership numbers (1,635,015 shares instead of 1,581,682 shares), a higher beneficial ownership percentage (21% instead of 20.5%), higher fully vested stock options (712,833 stock options instead of 659,500 stock options) and higher total stock options beneficially owned (746,166 stock options instead of 692,833 stock options) than should have been reported in rows (7), (9), (11), (13) and footnotes 2 and 3 of the cover page of Amendment No. 4, as applicable, and Items 3, 4 and 5 of Amendment No. 4, as applicable.

     

    Except as specifically amended below, all other provisions of the Schedule 13D remain in effect.

     

    Item 1. Security and Issuer.

     

    The information contained in “Item 1. Security and Issuer.” of the Schedule 13D is not being amended by this Amendment No. 5.

     

    Item 2. Identity and Background.

     

    The information contained in “Item 2. Identity and Background.” of the Schedule 13D is not being amended by this Amendment No. 5.

     

    Item 3. Source or Amount of Funds or Other Consideration.

     

    The information contained in “Item 3. Source or Amount of Funds or Other Consideration.” of the Schedule 13D is not being amended by this Amendment No. 5.

     

    Item 4. Purpose of Transaction.

     

    The information contained in rows (7), (8), (9), (10), (11) and (13) of the cover page of this Amendment No. 5 and the corresponding footnotes, and the information set forth in or incorporated by reference in Item 2, Item 3, Item 5 and Item 6 of this Amendment No. 5 is hereby incorporated by reference in its entirety into this Item 4.

     

    Except as described above, the information contained in “Item 4. Purpose of Transaction.” of the Schedule 13D is not being amended by this Amendment No. 5.

     

    Item 5. Interest in Securities of the Issuer.

     

    The responses to rows (7) through (13) of the cover page of this Amendment No. 5 and the corresponding footnotes are hereby incorporated by reference in their entirety in this Item 5.

     

    (a)       See responses to Items 11 and 13 on the cover page.

     

    (b)      See response to Rows (7), (8), (9) and (10) on the cover page.

     

     

     

     

     CUSIP No. 53630L100 Amendment No. 5 to Schedule
    13D
     Page 4 of 5 Pages

     

    (c)       Except as otherwise set forth in the Schedule 13D, the Reporting Person has not, to the best of his knowledge, engaged in any transaction with respect to the Common Stock of the Issuer during the sixty days prior to the date of filing this Amendment No. 5.

     

    Except as described above, the information contained in “Item 5. Interest in Securities of the Issuer.” of the Schedule 13D is not being amended by this Amendment No. 5.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    The information contained in “Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.” of the Schedule 13D is not being amended by this Amendment No. 5.

     

    Item 7. Material to be filed as Exhibits. 

     

    The information contained in “Item 7. Material to be filed as Exhibits.” of the Schedule 13D is not being amended by this Amendment No. 5.

     

     

     

     

     CUSIP No. 53630L100 Amendment No. 5 to Schedule
    13D
     Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: May 6, 2024  
      /s/ Jonathan H. Kaufman
      Name: Jonathan H. Kaufman

     

     

     

    Get the next $LIPO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LIPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      4/7/25 7:16:11 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/17/25 8:12:52 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/11/25 8:01:27 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    SEC Filings

    See more
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/25/25 3:14:40 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/20/25 4:02:53 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/16/25 4:25:47 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:09:22 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:00:15 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

      SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      10/17/24 5:00:44 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      5/15/24 4:39:19 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/19/24 6:21:08 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

      PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange. In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitmen

      6/25/25 3:15:00 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

      PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company's common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq's determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Spec

      6/20/25 3:19:25 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

      PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled "Systems and Methods of Detecting Interstitial Cystitis." The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions. The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. "This method can potentially provide enha

      6/17/25 8:30:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care